134 related articles for article (PubMed ID: 17229076)
21. [Mutation in the MSH2 gene in Muir-Torre syndrome].
Godard V; Coulet F; Bernaudin JF; Housset M; Soubrier F
Ann Dermatol Venereol; 1999; 126(8-9):600-3. PubMed ID: 10530347
[TBL] [Abstract][Full Text] [Related]
22. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
Yilmaz R; Akoglu H; Kirkpantur A; Kilickap S; Arici M; Altun B; Aki T; Erdem Y; Yasavul U; Turgan C
Ren Fail; 2007; 29(1):103-5. PubMed ID: 17365918
[TBL] [Abstract][Full Text] [Related]
23. Ocular Adnexal Adenomatoid Sebaceous Gland Hyperplasia: A Clinical and Immunopathologic Analysis in Relation to the Muir-Torre Syndrome.
Jakobiec FA; Cortes Barrantes P; Milman T; Lee NG; Fay A
Ophthalmic Plast Reconstr Surg; 2020; 36(1):e6-e12. PubMed ID: 31593035
[TBL] [Abstract][Full Text] [Related]
24. Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation.
Hayes D; Adler B; Turner TL; Mansour HM
Pediatr Neurol; 2014 Mar; 50(3):272-5. PubMed ID: 24405697
[TBL] [Abstract][Full Text] [Related]
25. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review.
Rishi K; Font RL
Ophthalmic Plast Reconstr Surg; 2004 Jan; 20(1):31-6. PubMed ID: 14752307
[TBL] [Abstract][Full Text] [Related]
26. [Muir-Torre syndrome with previously undescribed frameshift mutation in the MSH2 gene].
Gilly B; Unholzer A; Strobl-Wildemann G; Haas C; Starz H; Welzel J
Hautarzt; 2013 Apr; 64(4):290-4. PubMed ID: 23229822
[TBL] [Abstract][Full Text] [Related]
27. The cutaneous effects of post-transplant immunosuppression with cyclosporine in Muir-Torre syndrome.
Griffard EA; McCoppin HH; Wieberg J; Feldman M
J Am Acad Dermatol; 2011 May; 64(5):e86-7. PubMed ID: 21496695
[No Abstract] [Full Text] [Related]
28. A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene.
Vernez M; Hutter P; Monnerat C; Halkic N; Gugerli O; Bouzourene H
Fam Cancer; 2007; 6(1):141-5. PubMed ID: 17051350
[TBL] [Abstract][Full Text] [Related]
29. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
[TBL] [Abstract][Full Text] [Related]
30. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
31. Muir-Torre syndrome.
Navi D; Wadhera A; Fung MA; Fazel N
Dermatol Online J; 2006 Sep; 12(5):4. PubMed ID: 16962019
[TBL] [Abstract][Full Text] [Related]
32. Muir-Torre syndrome.
Cohen PR; Kohn SR; Davis DA; Kurzrock R
Dermatol Clin; 1995 Jan; 13(1):79-89. PubMed ID: 7712655
[TBL] [Abstract][Full Text] [Related]
33. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation.
Arnold A; Payne S; Fisher S; Fricker D; Soloway J; White SM; Novelli M; MacDonald K; Mackay J; Groves R; Canham N
Fam Cancer; 2007; 6(3):317-21. PubMed ID: 17323113
[TBL] [Abstract][Full Text] [Related]
34. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
Lo A; Egidi MF; Gaber LW; Shokouh-Amiri MH; Nazakatgoo N; Fisher JS; Gaber AO
Clin Transplant; 2004 Feb; 18(1):53-61. PubMed ID: 15108771
[TBL] [Abstract][Full Text] [Related]
35. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
Stallone G; Schena A; Infante B; Di Paolo S; Loverre A; Maggio G; Ranieri E; Gesualdo L; Schena FP; Grandaliano G
N Engl J Med; 2005 Mar; 352(13):1317-23. PubMed ID: 15800227
[TBL] [Abstract][Full Text] [Related]
36. [Sebaceous tumors and Muir-Torre syndrome].
Bourlond F; Cribier B; Lipsker D; Velter C
Ann Dermatol Venereol; 2015; 142(6-7):456-9. PubMed ID: 25890836
[No Abstract] [Full Text] [Related]
37. Skin lesions with Lynch syndrome could represent Muir-Torre syndrome.
Siddiqui N; Tariq Z; Gaba C; Hamouda D; Nawras A; Ul Rehman S; Mohamed IE
Int J Colorectal Dis; 2014 Aug; 29(8):1013-4. PubMed ID: 24793211
[No Abstract] [Full Text] [Related]
38. A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts.
Youseff N; Small S
Transplant Proc; 2002 Aug; 34(5):1653-5. PubMed ID: 12176522
[No Abstract] [Full Text] [Related]
39. Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution.
Toth CC; Burak K; Becker W
Headache; 2005 Mar; 45(3):245-6. PubMed ID: 15836601
[TBL] [Abstract][Full Text] [Related]
40. Aggressive Extraocular Sebaceous Carcinoma of the Scalp Involving the Brain in a Patient With Muir-Torre Syndrome.
Hadravsky L; Kazakov DV; Stehlik J; Michal M; Curik R; Krupa P; Skalova A; Kacerovska D
Am J Dermatopathol; 2016 Aug; 38(8):618-22. PubMed ID: 26779764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
